查詢結果分析
來源資料
相關文獻
- Lipid Peroxidation and Null Glutathione S-transferase GSTM1 Genotype in Epileptics with Anticonvulsant Therapy
- 癲癎病例報告
- 迷走神經刺激--癲癎的另一種治療方法
- 具熱痙攣病史之癲癎學童的智力特性研究
- 以Phenobarbital和phenytoin治療新生兒癲癎之比較
- 癲癎病患生活品質之探討
- 精神疾病藥物治療病案討論(9)--Carbamazepine引發之不良皮膚反應
- Lateralization and Prognostic Value of Proton Magnetic Resonance Spectroscopy in Patients with Intractable Temporal Lobe Epilepsy
- An 11-Year Old Boy with Short Stature, Psychomotor Retardation and Seizure
- 癲癎的新治療藥物
頁籤選單縮合
題 名 | Lipid Peroxidation and Null Glutathione S-transferase GSTM1 Genotype in Epileptics with Anticonvulsant Therapy=脂質過氧化產物與缺損型麩胱甘太轉換酵素基因在癲癎患者之研究 |
---|---|
作 者 | 劉青山; 吳鴻明; 蔡靜姍; 郭珍菱; 黃建財; | 書刊名 | 秀傳醫學雜誌 |
卷 期 | 3:1 2001.01[民90.01] |
頁 次 | 頁1-6 |
分類號 | 415.932 |
關鍵詞 | 麩胱甘太轉換酵素基因; 癲癎; 脂質過氧化產物; Glutathione s-transferase genotype; Epilepsy; Malondialdehyde; |
語 文 | 英文(English) |
中文摘要 | 針對54個良好控制癲癇患者及48位頑固型癲癇患者,分別進行缺損劉麩胱甘太轉換酵素基(GSTMI (-))之檢定與脂質過氧化產物(MDA),另同時針對110個健康者做對照組,我們發現頑固型癲癇患者對良好控制癲癇患者俱有高比例之GSTMI(-)(OR=4.7, 95% CI=1.9-11.5, P=0.001),與正常對照組亦有較高比例之GSTMI(-)(OR=2.5, 95% CI=1.0-6.1, P=0.047)。同時這些頑固型癲癇患者對良好控制癲癇患者俱有高比例之MDA(95% CI=0.2-0.9, P=0.002)與正常對照組亦有較高比例之GSTMI(-)(95%世隔絕CI=0.7-2.0, P=0.001)。在頑固型癲癇患者且帶有GSTMI(-)基因,其血清有較高之MDA產生。結論顯示,頑固型癲癇患者常帶有較高比例之GSTMI基因型,其原因可能是此類基因型患者體內無法產生足夠之CST酵素,以致無法完全消除帶有自山基特性之抗癲癇藥物代謝物質,以致造成腦部持續不正常放電。 |
英文摘要 | We examined the null genotype of glutathione S-transferase class μ (GSTMI (-)) and the level of serum lipid peroxides (measured as malondialdehyde, MDA) in 54 epileptics with good seizure control by mono-anticonvulsant therapy and 48 epileptics with intractable seizure under poly-anticonvulsant therapy. One hundred and ten healthy controls were also included. We found that the frequency of GSTMI (-) of the patients of the group with intractable seizure was significantly higher than those of the group with good seizure control (OR=4.7, 95% CI=1.9-11.5, P=0.001) and of the normal healthy subjects (OR=2.5, 95% CI=1.0-6.1, P=0.047). Significant elevation of serum MBA was also noted in the group of patients with intractable seizure as compared with the group of patients with good seizure control (3.4±2.1 μM vs 2.4±0.8 (M, 95% CI=0.2-0.9. P=0.002) and normal subjects (3.4±2.1 μM±1.9±1.1μM 95% CI=0.7-2.0, P=0.001). Moreover, the average serum level of MDA of the patients with GSTMI (-) genotype was higher than that of GSTMI (+) epileptics (3.4±1.8 (μM vs 2.3±0.9 μM, 95% CI=0.3-2.0, P=0.011) with intractable seizure under poly-anticonvulsants therapy. These findings suggest that the GSTMI (-) genotype may be an important genetic factor involved in the response of epileptics patients to conventional anticonvulsant therapy via free radicals-induced lipid peroxidation in the brain. |
本系統中英文摘要資訊取自各篇刊載內容。